Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs <i>In vitro</i> and <i>In vivo</i>

Hiroshi Hirai, Hiroshi Sootome, Yoko Nakatsuru et al. · Molecular Cancer Therapeutics · 2010 · 938 citations · Full text

Medicine, Oncology, Pharmacology +17

Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia

Hagop M. Kantarjian, Deborah A. Thomas, Susan O’Brien et al. · Cancer · 2004 · 632 citations

Medicine, Oncology, Pharmacology +12

Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.

Amy S. Clark, Kip A. West, Samantha A. Streicher et al. · PubMed · 2002 · 591 citations

Life Sciences, Oncology, Pharmacology +17

PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability

Ana Silva, José Andrés Yunes, Bruno A. Cardoso et al. · Journal of Clinical Investigation · 2008 · 442 citations · Full text

Medicine, Cell Biology, Oncology +16

Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice

Michael G. Kharas, Rachel Okabe, Jared J. Ganis et al. · Blood · 2009 · 274 citations · Full text

Medicine, Hematology, Oncology +14